The only oral GLP-1 approved by the Food and Drug Administration so far is Novo Nordisk's Rybelsus, which treats Type 2 diabetes and raked in about $3.38 billion in sales in 2024
Variants like C677T and A1298C can reduce enzyme efficiency, potentially leading to higher homocysteine levels and impacting processes like detoxification, neurotransmitter production, and cardiovascular health
Miranda-Ribera A, Miranda-Ribera A, Ennamorati M, Serena G, Cetinbas M, Lan J, Sadreyev RI, Jain N, Fasano A, Fiorentino M
Most RWS were burdened by a relatively small sample size and lack of thorough information regarding adherence to treatment and average dose used